Benzinga's Volume Movers

Cancer Genetics

shares moved up 6.38% to $20.85. The volume of Cancer Genetics shares traded was 1637% higher than normal. Cancer Genetics is expected to post revenue of $ 18.65 million in the year ending December, 2014. Global Payments

shares rose 9.25% to $55.39. The volume of Global Payments shares traded was 1130% higher than normal. Global Payments reported upbeat fiscal first-quarter results and raised its annual forecast. The company named Jeffrey S. Sloan as its new chief executive and announced its plans to buy back up to $100 million of its common stock. Rockwell Medical

shares climbed 7.69% to $12.32. The volume of Rockwell Medical shares traded was 482% higher than normal. Rockwell Medical reported that the Phase 3 CRUISE study data has been accepted as a Late-Breaking Clinical Trial. Allot Communications

surged 11.80% to $14.12. The volume of Allot Communications shares traded was 459% higher than normal. Allot Communications reported that it has received a new multimillion dollar order from a US-based cloud provider.